Our Take
A queueing-theory model that turns purification optimization into a map-and-decide tool, not guesswork—but only if your team actually documents process times and stability windows first.
Why it matters
Biomanufacturers routinely face the speed-or-quality trap in chromatography. This model gives them a framework to quantify the real cost of each intervention and avoid the trap of under-investing upstream only to risk product degradation waiting downstream.
Do this week
Bioprocessing lead: characterize processing times and stability windows at each chromatography step this month, then build a reference map of intervention costs and their effects on both quality and lead time so you can use it on the floor.
A model for chromatography optimization under time constraint
Researchers at Bilkent University, Northeastern University, and Indian Institute of Management Bangalore have developed an analytical model based on queueing network theory to guide optimization decisions in two-step chromatographic purification. The model addresses a practical problem: how to balance purity, processing time, and product stability when each intervention carries tradeoffs.
The team, led by Yasemin Limon, PhD, divides purification interventions into two types. Type I improves batch quality without increasing processing time (selecting better resins or reagents). Type II improves both quality and processing time but slows the process (reducing flow rates). The model evaluates how each intervention affects stage-specific lead-time constraints and probability of quality enhancement.
The key finding: intervention decisions at the first chromatography step directly constrain options at the second step. Under-investing upstream pushes purification burden downstream, where longer processing times risk product deterioration.
Interdependent decisions require a map, not instinct
Biopharmaceutical manufacturers must decide where to intervene aggressively and where to hold back—decisions that are not independent. A tighter stability window downstream forces more aggressive purification upstream. A cheaper Type I intervention at step one may increase congestion at step two, forcing a costly Type II intervention later.
The model translates these tradeoffs into actionable policy. Instead of optimizing each step in isolation, manufacturers can estimate their own process parameters (batch arrival rates, processing times, stability limits, intervention costs, and quality effects) and use the model to identify the optimal intervention policy under those specific conditions.
As the researchers note, "optimal intervention efforts change with costs." A decision map built early, before manufacturing decisions harden, reduces the risk of manufacturing lead-time violations and product quality loss.
Document stability windows and process times before you decide
The model is only useful if your team has characterized the input data. You must quantify how interventions change processing time, congestion, and feasibility with respect to stability-based time windows. Without this data, the model is a framework with no ground truth.
Start by documenting processing times at each chromatography step and the stability-based time windows for your product. Then map the range of operating conditions typically encountered in your facility, along with possible interventions, their costs, and stability-based time effects. Use this reference chart repeatedly on the manufacturing floor to guide real-time decisions. Distinguish carefully between Type I interventions (quality without time cost) and Type II interventions (quality with time cost); they affect lead time and feasibility differently. When stability constraints change (new molecular stability data, for example), do not evaluate them in isolation. Re-run the model to see how the optimal intervention policy shifts across both steps.